Clinical trial
A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications, and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation
NCT06628687 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications, and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation
- Lead sponsor
- Biogen
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- October 26, 2026
- Completion date
- April 30, 2035
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.